Metastatic Colorectal Cancer (MCRC) Clinical Trial
Official title:
A Blinded, Randomized, Phase 1/2 Study of Brivanib Alaninate vs Placebo in Combination With Erbitux and Irinotecan K-Ras Wildtype Subjects With Metastatic Colorectal Cancer
Part 1: To define the recommended dose of brivanib that can be safely administered in
combination with Erbitux (Cetuximab) and irinotecan to subjects with advanced metastatic
colorectal cancer (MCRC)
Part 2: To compare median duration of progression free survival (PFS)
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02069704 -
Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients
|
Phase 1 | |
| Recruiting |
NCT05286814 -
M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma
|
Phase 2 | |
| Completed |
NCT01705002 -
Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.
|
Phase 1 | |
| Recruiting |
NCT03829462 -
Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients
|
Phase 3 | |
| Recruiting |
NCT04856787 -
A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05970302 -
XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC
|
Phase 2 | |
| Completed |
NCT05420909 -
A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC)
|
||
| Not yet recruiting |
NCT06089330 -
A Study of JMT101 in Patients With Metastatic Colorectal Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT02649790 -
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03511963 -
A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC
|
Phase 3 | |
| Active, not recruiting |
NCT05839951 -
An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions
|